Progression, Remission and Regression of Chronic Renal Diseases

Monica Cortinovis, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Progression to end-stage renal disease is common in chronic nephropathies, independent of the initial insult. While genetic factors may contribute to susceptibility and progression of renal disease, proteinuria has been documented as an independent predictor of outcome. Reduction of urinary protein levels by restoration of glomerular sieving function with renin-angiotensin system (RAS) blockers has been shown to limit renal function decline in individuals with non-diabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. In animal models, regression of glomerular structural changes is associated with remodeling of glomerular architecture. This review briefly describes our understanding of the mechanism of renal disease progression, the therapeutic advantages of ameliorating glomerular sieving dysfunction and proteinuria of RAS inhibitors and how remission/regression of renal injury can be achieved with multifactorial interventions.

Original languageEnglish
JournalNephron
DOIs
Publication statusAccepted/In press - Apr 21 2016

Fingerprint

Chronic Renal Insufficiency
Kidney
Renin-Angiotensin System
Proteinuria
Disease Progression
Diabetic Nephropathies
Chronic Kidney Failure
Animal Models
Wounds and Injuries
Proteins
Therapeutics

Keywords

  • Chronic renal disease
  • Regression
  • Remission
  • Renin-angiotensin system#

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Urology
  • Physiology (medical)

Cite this

Progression, Remission and Regression of Chronic Renal Diseases. / Cortinovis, Monica; Ruggenenti, Piero; Remuzzi, Giuseppe.

In: Nephron, 21.04.2016.

Research output: Contribution to journalArticle

@article{a6e30936c90844d1b119acb243f17aba,
title = "Progression, Remission and Regression of Chronic Renal Diseases",
abstract = "Progression to end-stage renal disease is common in chronic nephropathies, independent of the initial insult. While genetic factors may contribute to susceptibility and progression of renal disease, proteinuria has been documented as an independent predictor of outcome. Reduction of urinary protein levels by restoration of glomerular sieving function with renin-angiotensin system (RAS) blockers has been shown to limit renal function decline in individuals with non-diabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. In animal models, regression of glomerular structural changes is associated with remodeling of glomerular architecture. This review briefly describes our understanding of the mechanism of renal disease progression, the therapeutic advantages of ameliorating glomerular sieving dysfunction and proteinuria of RAS inhibitors and how remission/regression of renal injury can be achieved with multifactorial interventions.",
keywords = "Chronic renal disease, Regression, Remission, Renin-angiotensin system#",
author = "Monica Cortinovis and Piero Ruggenenti and Giuseppe Remuzzi",
year = "2016",
month = "4",
day = "21",
doi = "10.1159/000445844",
language = "English",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Progression, Remission and Regression of Chronic Renal Diseases

AU - Cortinovis, Monica

AU - Ruggenenti, Piero

AU - Remuzzi, Giuseppe

PY - 2016/4/21

Y1 - 2016/4/21

N2 - Progression to end-stage renal disease is common in chronic nephropathies, independent of the initial insult. While genetic factors may contribute to susceptibility and progression of renal disease, proteinuria has been documented as an independent predictor of outcome. Reduction of urinary protein levels by restoration of glomerular sieving function with renin-angiotensin system (RAS) blockers has been shown to limit renal function decline in individuals with non-diabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. In animal models, regression of glomerular structural changes is associated with remodeling of glomerular architecture. This review briefly describes our understanding of the mechanism of renal disease progression, the therapeutic advantages of ameliorating glomerular sieving dysfunction and proteinuria of RAS inhibitors and how remission/regression of renal injury can be achieved with multifactorial interventions.

AB - Progression to end-stage renal disease is common in chronic nephropathies, independent of the initial insult. While genetic factors may contribute to susceptibility and progression of renal disease, proteinuria has been documented as an independent predictor of outcome. Reduction of urinary protein levels by restoration of glomerular sieving function with renin-angiotensin system (RAS) blockers has been shown to limit renal function decline in individuals with non-diabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. In animal models, regression of glomerular structural changes is associated with remodeling of glomerular architecture. This review briefly describes our understanding of the mechanism of renal disease progression, the therapeutic advantages of ameliorating glomerular sieving dysfunction and proteinuria of RAS inhibitors and how remission/regression of renal injury can be achieved with multifactorial interventions.

KW - Chronic renal disease

KW - Regression

KW - Remission

KW - Renin-angiotensin system#

UR - http://www.scopus.com/inward/record.url?scp=84964282354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964282354&partnerID=8YFLogxK

U2 - 10.1159/000445844

DO - 10.1159/000445844

M3 - Article

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

ER -